$2.59
-0.04 (-1.52%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where VERU is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
12 interventional · 3 with posted results
Held by 5 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC, CITADEL ADVISORS LLC, MARSHALL WACE, LLP, SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 6.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight LossNCT07446998To determine the effect of enobosarm in combination with semaglutide on total body weight compared to semaglutide alone.Randomized · Triple-masked · Treatment | Phase 2 | Recruiting | Drug: Enobosarm, Semaglutide (Wegovy) weekly injection | Obesity & Overweight, Mobility Disability, HOMA-IR | 200 | Oct 2027 | ≤ 438 d | 2026-07-01 |
| Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight MgmtNCT06282458The primary endpoint for the study is the percentage change from baseline in total lean body mass at 112 days.Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Enobosarm, Semaglutide | Muscle Loss, Obesity | 168 | 2025-04-11actual | — | 2025-09-17 |
| Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast CancerNCT05079360Efficacy of sabizabulin in the treatment of estrogen receptor positive (ER+HER2) metastatic breast cancer (MBC)Randomized · Single-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Decided to halt and will potentially reopen in the future. | Drug: Sabizabulin, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator | Metastatic Breast Cancer | 0 | 2024-03-30 | — | 2023-03-24 |
| Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast CancerNCT04869943To demonstrate the efficacy of Enobosarm in the treatment of androgen receptor positive (AR+) and estrogen receptor positive (ER+) metastatic breast cancer (MBC) as measured by radiographic progression free survival (rPFS).Randomized · Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: Business decision | Drug: Enobosarm, Exemestane | Metastatic Breast Cancer | 52 | 2024-01-09actual | — | 2024-01-26 |
| Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast CancerNCT05065411Primary endpoint for the study is the median progression free survival (PFS) in the Enobosarm Combination Group compared to the Control Treatment Group in patients with AR% nuclei staining ≥40%. Progression will be defined based on RECIST 1.1 criteriaRandomized · Single-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Business decision | Drug: Enobosarm & Abemaciclib Combo, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant | Metastatic Breast Cancer | 5 | 2023-10-19actual | — | 2024-02-26 |
| Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting AgentNCT04844749Efficacy of VERU-111 in the treatment of metastatic castration-resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agentRandomized · Single-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Administrative reasons | Drug: VERU-111, Enzalutamide, Abiraterone | Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer | 105 | 2023-05-04actual | — | 2024-02-05 |
| To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate CancerNCT03752099Maximum Tolerated DoseRandomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Administrative decision | Drug: VERU-111 | Metastatic Castration Resistant Prostate Cancer | 80 | 2023-03-15actual | — | 2023-09-26 |
| To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate CancerNCT04843319Percent of men with total testosterone at <50 ng/dL by day 28Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Study terminated as end points were not achieved at current dose level. | Drug: VERU-100 | Advanced Prostate Adenocarcinoma | 24 | 2023-01-19actual | — | 2023-05-19 |
| P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .NCT05008510To compare the efficacy of sabizabulin monotherapy to Sacituzumab govitecan-hziy monotherapyRandomized · Single-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Decided to halt and will potentially reopen in the future. | Drug: Sabizabulin, Sacituzumab Govitecan-hziy, Sabizabulin/Sacituzumab govitecan-hziy Combo | Metastatic Triple Negative Breast Cancer | 0 | 2022-07-30 | — | 2022-02-08 |
| VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on StudyNCT04842747results2023-04-18Efficacy of Sabizabulin in the Treatment of SARS-CoV-2 Infection by Assessing Its Effect on the Proportion of Patients Who Died on Study.Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: VERU-111 | SARS-CoV Infection | 204 | 2022-07-06actual | — | 2023-04-18 |
| COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111NCT04388826results2021-11-24Number of Subjects That Are Alive Without Respiratory Failure at Day 29.Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Veru-111 | Respiratory Distress Syndrome, Adult | 39 | 2020-12-18actual | — | 2022-10-27 |
| Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate CancerNCT03646162results2021-06-18Change in Frequency of Moderate to Severe Hot Flashes at 6 WeeksRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Veru-944, Placebo | Prostate Cancer Metastatic | 93 | 2020-04-30actual | — | 2021-12-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19